IMMUNE-MEDIATED BILE DUCT INJURY IN BILIARY ATRESIA
Project Number5R03DK057829-02
Former Number1R01DK057829-01
Contact PI/Project LeaderKRAMS, SHERI M.
Awardee OrganizationSTANFORD UNIVERSITY
Description
Abstract Text
DESCRIPTION (adapted from the application)
Biliary atresia is a very serious disease of the newborn in which there is an
obliteration or discontinuity of the biliary system. The incidence of this
neonatal cholestatic disorder is 1 in 10,000 live births worldwide. If left
untreated biliary atresia leads to end-stage liver disease with a median
survival of eight months after birth. Thus, biliary atresia is the most common
indication for pediatric liver transplantation. The etiology remains unknown
and there is little information on disease progression. We have obtained
preliminary data to explain the localization of specific lymphocyte subsets to
biliary atresia liver. Furthermore, we have identified candidate mediators of
cholangiocyte cell death. The objective of this research is to elucidate the
immune mediated events which lead to lymphocyte accumulation in the liver and
destruction of the bile ducts. In Specific Aim 1 we propose to establish the
expression pattern of the chemokines in biliary atresia liver and confirm that
lymphocytes with receptors for these chemokines traffic to the liver. Liver
tissue from patients with biliary atresia will be analyzed by ribonuclease
protection assays and immunohistochemical staining to identify specific
chemokines as well as their cellular source and the T cell subsets bearing
receptors for these chemokines. Specific Aim 2 will establish if apoptosis is
involved in the bile duct obliteration in biliary atresia. Specifically, we
will determine the extent and localization of apoptotic cells in biliary
atresia liver. In addition, we will examine biliary atresia liver for the
presence of well-defined mediators of apoptosis and determine the subsets of
infiltrating cells which express these mediators. In Specific Aim 3 we will
utilize cDNA microarray strategies to compare gene expression patterns in
biliary atresia at early and late stages of disease as well as to other
cholestatic liver pathologies. This approach will offer opportunities to
identify known and novel genes which participate in the pathogenesis of biliary
atresia. We anticipate that these studies will provide unique insights into the
pathogenesis of biliary atresia and form the groundwork for future studies
related to this severe and enigmatic liver disease.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
RNase protection assayT lymphocyteapoptosisbiliary atresiacell migrationchemokinecytokine receptorsgene expressionhuman subjectinfant human (0-1 year)microarray technologypathologic process
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
848
DUNS Number
009214214
UEI
HJD6G4D6TJY5
Project Start Date
30-September-2000
Project End Date
30-June-2003
Budget Start Date
01-July-2001
Budget End Date
30-June-2003
Project Funding Information for 2001
Total Funding
$78,200
Direct Costs
$50,000
Indirect Costs
$28,200
Year
Funding IC
FY Total Cost by IC
2001
National Institute of Diabetes and Digestive and Kidney Diseases
$78,200
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R03DK057829-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R03DK057829-02
Patents
No Patents information available for 5R03DK057829-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R03DK057829-02
Clinical Studies
No Clinical Studies information available for 5R03DK057829-02
News and More
Related News Releases
No news release information available for 5R03DK057829-02
History
No Historical information available for 5R03DK057829-02
Similar Projects
No Similar Projects information available for 5R03DK057829-02